These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 22247060)

  • 1. Mid-term outcome after endovascular therapy in the superficial femoral and popliteal artery using long stents.
    Schoenefeld E; Donas KP; Schönefeld T; Osada N; Austermann M; Torsello G
    Vasa; 2012 Jan; 41(1):49-56. PubMed ID: 22247060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent.
    Nguyen BN; Conrad MF; Guest JM; Hackney L; Patel VI; Kwolek CJ; Cambria RP
    J Vasc Surg; 2011 Oct; 54(4):1051-1057.e1. PubMed ID: 21636240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary stenting of the superficial femoral and popliteal artery.
    Dearing DD; Patel KR; Compoginis JM; Kamel MA; Weaver FA; Katz SG
    J Vasc Surg; 2009 Sep; 50(3):542-7. PubMed ID: 19540706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
    Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
    J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of endovascular interventions for TASC II B and C femoropopliteal lesions.
    Baril DT; Marone LK; Kim J; Go MR; Chaer RA; Rhee RY
    J Vasc Surg; 2008 Sep; 48(3):627-33. PubMed ID: 18727966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis.
    Mohr PJ; Oyama JK; Luu JT; Stinis CT
    Cardiovasc Revasc Med; 2015 Dec; 16(8):465-8. PubMed ID: 26483319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and long-term outcome of Silverhawk assisted atherectomy for femoro-popliteal lesions according the TASC II classification: a single-center experience.
    Sixt S; Rastan A; Beschorner U; Noory E; Schwarzwälder U; Bürgelin K; Schwarz T; Müller C; Hauk M; Brantner R; Möhrle C; Linnemann B; Macharzina R; Neumann FJ; Zeller T
    Vasa; 2010 Aug; 39(3):229-36. PubMed ID: 20737381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of spot stenting versus long stenting after intentional subintimal approach for long chronic total occlusions of the femoropopliteal artery.
    Hong SJ; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2015 Mar; 8(3):472-480. PubMed ID: 25703873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of statin therapy with the primary patency of femoral and popliteal artery stents.
    de Grijs D; Teixeira P; Katz S
    J Vasc Surg; 2018 May; 67(5):1472-1479. PubMed ID: 29224939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    JACC Cardiovasc Interv; 2014 Jul; 7(7):792-8. PubMed ID: 25060024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MISAGO 2: one-year outcomes after implantation of the Misago self-expanding nitinol stent in the superficial femoral and popliteal arteries of 744 patients.
    Schulte KL; Kralj I; Gissler HM; Bagnaschino LA; Buschmann I; Pernès JM; Haage P; Goverde P; Beregi JP; Válka M; Boudny J; Geibel T; Velkoborsky M; Zähringer M; Paetzel C; Fanelli F; Müller-Hülsbeck S; Zeller T; Langhoff R
    J Endovasc Ther; 2012 Dec; 19(6):774-84. PubMed ID: 23210876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The success of endovascular therapy for all TransAtlantic Society Consensus graded femoropopliteal lesions.
    Han DK; Shah TR; Ellozy SH; Vouyouka AG; Marin ML; Faries PL
    Ann Vasc Surg; 2011 Jan; 25(1):15-24. PubMed ID: 20932714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease.
    Geraghty PJ; Mewissen MW; Jaff MR; Ansel GM;
    J Vasc Surg; 2013 Aug; 58(2):386-95.e4. PubMed ID: 23676191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes for systematic primary stent placement in complex iliac artery occlusive disease classified according to Trans-Atlantic Inter-Society Consensus (TASC)-II.
    Ichihashi S; Higashiura W; Itoh H; Sakaguchi S; Nishimine K; Kichikawa K
    J Vasc Surg; 2011 Apr; 53(4):992-9. PubMed ID: 21215582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions.
    Bosiers M; Deloose K; Callaert J; Moreels N; Keirse K; Verbist J; Peeters P
    J Vasc Surg; 2011 Oct; 54(4):1042-50. PubMed ID: 21636239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
    Ullery BW; Tran K; Itoga N; Casey K; Dalman RL; Lee JT
    J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.